Electrophysiology

St. Joseph's Children's Hospital First in Tampa Bay to Implant Leadless Pacemaker in Pediatric Heart Patient

Retrieved on: 
Friday, February 2, 2024

TAMPA, Fla., Feb. 2, 2024 /PRNewswire/ -- The Patel Children's Heart Institute at St. Joseph's Children's Hospital recently implanted its first leadless pacemaker, the first among all Tampa Bay hospitals to leverage this advanced technology in a pediatric patient.

Key Points: 
  • TAMPA, Fla., Feb. 2, 2024 /PRNewswire/ -- The Patel Children's Heart Institute at St. Joseph's Children's Hospital recently implanted its first leadless pacemaker, the first among all Tampa Bay hospitals to leverage this advanced technology in a pediatric patient.
  • The procedure was performed by Dr. Kelvin Lau, director of pediatric electrophysiology at St. Joseph's Children's Hospital, on a teenage girl who was born with isolated congenital heart block.
  • The Patel Children's Heart Institute at St. Joseph's Children's Hospital is home to the Tampa Bay area's only comprehensive congenital heart disease program.
  • A partnership between St. Joseph's Children's Hospital and UPMC Children's Hospital of Pittsburgh provides families across Florida with unprecedented access to the highest level of pediatric heart care available.

CathVision to Showcase ECGenius System and AI Algorithms at AF Symposium 2024

Retrieved on: 
Tuesday, January 30, 2024

COPENHAGEN, Denmark, Jan. 30, 2024 /PRNewswire/ -- CathVision today announced the ECGenius™ System will be featured in a Spotlight Session led by Dr. Larry Chinitz at the 29th Annual International AF Symposium in Boston, February 1-3, and highlighted at the CathVision booth (#419).1

Key Points: 
  • He will detail his experiences with CathVisions's advanced EP recording system, discussing how the acquisition of high-fidelity, low-noise cardiac electrograms create the necessary foundation to implement intelligent, automated analyses provided by the CARDIALYTICS™ AI algorithms.
  • "AI in the EP Lab: Replacing Legacy EP Recording Standards with ECGenius and AI-Algorithms to Effectively Measure Success of Ablation Outcomes"
    Reinforcing the benefits of the ECGenius System, two poster presentations will also be shared during the AF Symposium featuring data from studies conducted at the University of Vermont.
  • ECGenius System and our CARDIALYTICS AI algorithms deliver the quality and streamlined processes to capture, assess, and ablate confidently."
  • For more information about ECGenius System and CARDIALYTICS, or to meet with CathVision at the AF Symposium, please contact us and connect on LinkedIn .

Endologix Announces that Art Taylor Joins Board of Directors

Retrieved on: 
Thursday, January 25, 2024

Endologix LLC , a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, is pleased to announce that Art Taylor has been appointed to the Endologix Board of Directors.

Key Points: 
  • Endologix LLC , a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, is pleased to announce that Art Taylor has been appointed to the Endologix Board of Directors.
  • Art Taylor has over 30 years of experience in operational and financial executive leadership within the medical device, pharmaceutical, and high-tech industries.
  • Mr. Taylor served as a member of the Board of Directors for several medical device firms that were subsequently acquired and is currently a Board member for three early stage companies, and Providence Medical Technology, a commercial stage company.
  • "We are excited to welcome Art Taylor to the Endologix Board of Directors," expressed Matt Thompson, MD, President, and CEO of Endologix.

First Coast Cardiovascular Institute and CardioHealth Partner to Advance Cardiovascular Care for Northeast Florida Residents

Retrieved on: 
Monday, January 29, 2024

JACKSONVILLE, Fla., Jan. 29, 2024 /PRNewswire-PRWeb/ -- First Coast Cardiovascular Institute, a Cardiovascular Logistics partner practice that offers cardiovascular medicine, sleep medicine, pulmonology, and amputation prevention to residents in Northeast Florida and Southern Georgia, has joined forces with CardioHealth, a Jacksonville-based cardiovascular practice that specializes in delivering exceptional care to patients with hypertension, congestive heart failure, atrial fibrillation, and valvular heart disease. Together, they aim to advance cardiovascular care across Northeast Florida.

Key Points: 
  • Together, they aim to advance cardiovascular care across Northeast Florida.
  • "We are thrilled to partner with CardioHealth to provide the highest quality cardiovascular care to Northeast Florida patients," said Dr. Khatib, President of FCCI.
  • "We are thrilled to partner with CardioHealth to provide the highest quality cardiovascular care to Northeast Florida patients," said Dr. Khatib, President of FCCI.
  • "This collaboration between First Coast Cardiovascular Institute and CardioHealth marks a significant milestone for both practices," said David Konur, CEO of Cardiovascular Logistics.

PrepMD's Online Cardiac Healthcare Training Solutions Now Approved for CEUs

Retrieved on: 
Friday, January 26, 2024

BRAINTREE, Mass., Jan. 26, 2024 /PRNewswire/ -- PrepMD, the leading cardiac healthcare solutions provider, announced today the accreditation of their online healthcare training programs for Nursing Continuing Education Units (CEUs).

Key Points: 
  • BRAINTREE, Mass., Jan. 26, 2024 /PRNewswire/ -- PrepMD, the leading cardiac healthcare solutions provider, announced today the accreditation of their online healthcare training programs for Nursing Continuing Education Units (CEUs).
  • PrepMD's comprehensive online training solutions have long been recognized for their excellence in upskilling clinical staff in device clinics, EP Labs, and Cath Labs.
  • At PrepMD, we are committed to delivering the highest quality remote monitoring, staffing, and training solutions for cardiac healthcare providers.
  • With PrepMD's Online Training Programs now approved for Nursing CEUs, individuals can advance their knowledge and maintain their professional credentials conveniently and effectively.

Integer Holdings Corporation Announces Preliminary Unaudited Sales Results and Acquisition of Pulse Technologies

Retrieved on: 
Wednesday, January 10, 2024

PLANO, Texas, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading medical device outsource manufacturer, today announced fourth quarter 2023 preliminary unaudited sales are expected to be in the range of $411 million to $413 million, an increase of 10% to 11% compared to fourth quarter 2022. Preliminary unaudited full year 2023 sales are expected to be in the range of $1.595 billion to $1.597 billion, an increase of 16% compared to full year 2022.

Key Points: 
  • Based in Quakertown, Pennsylvania, Pulse Technologies also provides proprietary advanced technologies, including Hierarchical Surface Restructuring (HSR™), Scratch-Free Surface Finishes, and Titanium Nitride Coatings.
  • “The acquisition of Pulse Technologies is directly aligned with Integer’s strategy to expand our capabilities and capacity in targeted growth markets,” said Payman Khales, Integer President, Cardio & Vascular.
  • “We were immediately impressed with Pulse Technologies’ long-standing customer relationships, technical talent, unique technologies, shared values, and capacity for growth.
  • Pulse Technologies’ estimated full year 2023 sales are approximately $42 million with 2023 adjusted EBITDA(a) expected to be approximately $11 million.

Stereotaxis Announces First Patients Successfully Treated Using MAGiC Ablation Catheter

Retrieved on: 
Monday, January 8, 2024

ST. LOUIS, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announced that the first patients have been successfully treated using its Magnetic Interventional Ablation Catheter, MAGiC™.

Key Points: 
  • ST. LOUIS, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announced that the first patients have been successfully treated using its Magnetic Interventional Ablation Catheter, MAGiC™.
  • Stereotaxis’ MAGiC catheter is a robotically navigated magnetic ablation catheter designed to perform minimally invasive cardiac ablation procedures.
  • The first human procedures using the MAGiC catheter were successfully performed by Prof. Germanas Marinskis and Assoc.
  • “We were delighted to perform the first procedures using the MAGiC catheter, and were pleased with the performance,” said.

Autonomix Medical, Inc. Provides Business Overview and Highlights Upcoming Milestones

Retrieved on: 
Thursday, January 4, 2024

THE WOODLANDS, TX, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (“Autonomix” or the “Company”) a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today provided a business overview and highlighted upcoming milestones.

Key Points: 
  • THE WOODLANDS, TX, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (“Autonomix” or the “Company”) a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today provided a business overview and highlighted upcoming milestones.
  • Lori Bisson, Chief Executive Officer of Autonomix, commented, “Autonomix is dedicated to dramatically improving the quality of millions of lives by empowering the nerve-directed treatments of tomorrow.
  • Achieving “proof-of-concept” in this area could open the door to blockbuster diseases, expanding the horizons for the Company’s technology.
  • The smaller and shorter clinical trials potentially translate to more efficient resource utilization, minimizing overall development costs.

AtriCure Appoints Shlomi Nachman to the Board of Directors

Retrieved on: 
Thursday, January 4, 2024

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced it appointed Shlomi Nachman to its Board of Directors.

Key Points: 
  • AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced it appointed Shlomi Nachman to its Board of Directors.
  • Prior to that, Mr. Nachman served in various roles with increased scope and responsibilities, including Worldwide President of Biosense Webster and Cordis.
  • “I am thrilled to be joining the AtriCure Board during this exciting time of accelerating growth and profitability,” said Mr. Nachman.
  • I have done extensive diligence on the company’s business, prospects, and end user markets, and believe them to be significantly underpenetrated.

Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX™ Nanosecond Pulsed Field Ablation (nsPFA™) Cardiac Catheter

Retrieved on: 
Wednesday, December 20, 2023

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced the completion of the first five procedures in its first-in-human feasibility study with its novel CellFX nsPFA cardiac catheter.

Key Points: 
  • Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced the completion of the first five procedures in its first-in-human feasibility study with its novel CellFX nsPFA cardiac catheter.
  • The catheter is designed to deliver a fast, transmural and fully circumferential ablation in a single energy delivery.
  • The CellFX nsPFA cardiac catheter is integrated with 3D mapping and navigation to deliver a comprehensive visualization and precise ablation delivery solution.
  • The observations to date have been positive but the broad set of risks associated with cardiac surgery remain.